ADARx Pharmaceuticals

Claeboe joined ADARx in January 2022 with extensive experience in CGMP drug substance and drug product manufacturing through various stages of clinical development to commercialization. Fisher joined ADARx as our Vice President of Intellectual Property. Our mission is to turn cutting-edge science into life-saving therapeutics. To achieve our mission, we are committed to building an innovative, values-driven organization focused on our people, the advancement of our efficient drug platform and the creation of a deep pipeline of therapeutics to address intractable diseases. ADARx is developing a modality agnostic RNA targeting platform, including oligonucleotides for inhibition, degradation and editing, together with novel oligonucleotide delivery technologies. ADARx is currently focused on diseases in three therapeutic areas: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases. ADARx brings hope for people with intractable disease. The power in our name and of our technology is the ability to identify a wide range of disease targets and choose the best RNA targeting approach to deliver transformative precision therapeutics.